Life Sciences

The coronavirus pandemic hasn't stopped the Massachusetts biopharmaceutical industry from raising venture capital. In fact, the industry raised far more in the first half this year than it did the first six months of 2019, according to a report released Tuesday.

Biotech company Enrich Therapeutics Inc. of Worcester and Groton, Conn., has secured $320,000 in seed funding, the two-year-old company announced on Friday.

Udit Batra, the head of the Boston life sciences division of a German company, will replace outgoing Waters Corp. CEO and president Christopher O’Connell in September, the Milford health software company announced on Wednesday. 

Kevin Young, Web Industries vice president of the company's medical device manufacturing business, spoke with WBJ about what it's like to expand during a pandemic and why the company decided to beef up its Holliston operations. 

It’s been a worrying few months financially since the coronavirus pandemic hit in March – and that’s for those who’ve kept their job or their business in operation.

The Massachusetts Biotechnology Council sees the state's life sciences industry as more important than ever, with what it says are more than 85 companies working on tests, treatments and vaccines related to the coronavirus pandemic.

CRISPR Therapeutics, a Switzerland-based biopharmaceutical gene editing company, has announced it is building a new cell therapy manufacturing facility in Framingham.

Acton medical device company Insulet will begin powering its corporate headquarters and manufacturing facility with solar energy, the company announced on Wednesday.

Human resources technology company Workhuman, co-headquartered in Framingham and Dublin, Ireland, has been valued at $1.2 billion, officially making it a so-called unicorn company, according to its press release.

James McGorry resigned as CEO of Holliston biotechnology company Biostage, Inc., officially leaving his position on Feb. 7, according to a company quarterly earnings report released in May.